Neurocrine Biosciences (NBIX) Capital Expenditures (2010 - 2026)

Neurocrine Biosciences has reported Capital Expenditures for 17 years, with the latest figure at $9.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 14.95% year-over-year to $9.1 million; the trailing twelve-month figure through Mar 2026 stood at $32.4 million (down 32.22% YoY), and the FY2025 full-year result was $34.0 million, down 10.99% from the prior year.
• Capital Expenditures for Q1 2026 stood at $9.1 million, down from $33.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $33.4 million in Q4 2025, with the low at -$22.6 million in Q3 2025.
• Historically, Capital Expenditures has averaged $7.4 million across 5 years, with a median of $8.8 million in 2022.
• The largest YoY upside for Capital Expenditures was 872.73% in 2025 against a maximum downside of 379.01% in 2025.
• Neurocrine Biosciences' Capital Expenditures stood at $15.8 million in 2022, then soared by 73.42% to $27.4 million in 2023, then sank by 73.36% to $7.3 million in 2024, then soared by 357.53% to $33.4 million in 2025, then plunged by 72.75% to $9.1 million in 2026.
• The last three Capital Expenditures figures came in at $9.1 million (Q1 2026), $33.4 million (Q4 2025), and -$22.6 million (Q3 2025), per Business Quant data.